Gains and losses at chromosome 3p12-21 are common in breast tumors and associated with patient outcomes. We hypothesized that the LRIG1 gene at 3p14.1, whose product functions in ErbB-family member degradation, is a critical tumor modifier at this locus. We analyzed 971 stage I/II breast tumors using Affymetrix Oncoscan molecular inversion probe arrays that include 12 probes located within LRIG1. Copy number results were validated against gene expression data available in the public database. By partitioning the LRIG1 probes nearest exon 12/13, we confirm a breakpoint in the gene and show that gains and losses in the subregions differ by tumor and patient characteristics including race/ethnicity. In analyses adjusted for known prognostic factors, loss of LRIG1 was independently associated with risk of any relapse (HR, 1.90; 95% CI, 1.32-2.73), relapse ! 5 years (HR, 2.39; 95% CI, 1.31-4.36), and death (HR, 1.55; 95% CI, 1.11-2.16). Analyses of copy number across chromosome 3, as well as expression data from pooled, publicly available datasets, corroborated the hypothesis of an elevated and persistent risk among cases with loss of or low LRIG1. We concluded that loss/low expression of LRIG1 is an independent risk factor for breast cancer metastasis and death in stage I/II patients. Increased hazard in patients with loss/low LRIG1 persists years after diagnosis, suggesting that LRIG1 is acting as a critical suppressor of tumor metastasis and is an early clinical indicator of risk for late recurrences in otherwise low-risk patients. Cancer Res; 74(11); 2928-35. Ó2014 AACR. Figure 3. Kaplan-Meier curves for unadjusted analyses of time to DMFS (A) and overall survival (B) by level of LRIG1 gene expression. ---low, --medium, ---high. Thompson et al.
Introduction
The human LRIG1 gene at chromosome 3p14.1 encodes a "leucine-rich repeats and immunoglobulin-like domains-1" protein (1) that negatively regulates the ERRB2 gene product, human epidermal growth factor receptor 2 (HER2), and other oncogenic receptor tyrosine kinases, including EGFR, HER3 and 4, MET (hepatocyte growth factor receptor), and RET (rearranged during transfection; refs. [2] [3] [4] [5] . The LRIG1 protein is expressed in most tissues analyzed (6) and limits the size of epithelial progenitor cell populations by promoting the degradation of members of the ErbB family (7) (8) (9) . In mouse models, deletion results in epidermal hyperplasia (10, 11) and expansion of base columnar cells in the intestinal crypt (9) .
We previously analyzed LRIG1 copy number by in situ hybridization and showed increased copy number at exon 12/13 in 34% of 73 breast tumors (12, 13) . Moreover, we observed coincident ERBB2 gene amplification in tumors with gain of exon 12/13 probe signal. In another study, LRIG1 expression was observed to be downregulated in HER2overexpressing tumors (4) . Recently, high levels of LRIG1 expression were observed in estrogen receptor (ER) þ breast tumors with functional evidence for direct induction of LRIG1 expression by estrogen that was antagonized by HER2 (14) . Using pooled results from public expression array data, Krig and colleagues reported that LRIG1 overexpression in breast tumors was associated with lower risk of relapse, although analyses were not adjusted for clinical covariates (14) . These findings contrast with reports of chromosome 3 losses between p12 and p21 common in breast cancer, and Staaf and colleagues showed that loss of 3p13, adjusted for patient and clinical characteristics including ERBB2 amplification, was independently prognostic for recurrence and breast cancer death (15) .
To evaluate the clinical importance and correlates of the LRIG1 chromosomal region, we applied high-resolution molecular inversion probe (MIP) analysis in a cohort of early-stage breast tumors with long-term follow-up to characterize the effect of LRIG1 gene dose on patient outcomes, considering amplification of ERBB2.
Patients and Methods

Patients and specimen characteristics
Patients from the early stage breast cancer repository, a cohort of 2,327 women with stage I/II breast cancer, were treated at the University of Texas MD Anderson Cancer Center between 1985 and 2000. Details of the cohort have been reported, including methodology for medical record abstraction for clinical, pathological, and treatment covariates (16) . Of 2,327 women, 1,003 cases were Texas residents and had primary tumor tissue with >80% tumor cells from formalin-fixed, paraffin-embedded tissue. For copy number analyses, cases were matched $2:1 for non-Hispanic white (NHW)-to-Hispanic and NHW-to-black women, controlling for stage and age of diagnosis. Case status was last updated in 2007 with a median follow-up time of 8.9 years.
ER and progesterone receptor (PR) status were determined as described (17) . Intrinsic subtypes were defined as follows: luminal A: ER þ and/or PR þ and <15% Ki-67; luminal B: ER þ and/or PR þ and Ki-67 !15%; and triple-negative breast cancer (TNBC): ER À , PR, and HER2 À . HER2 þ tumors were defined based on ERRB2 gene copy number by MIP array with a threshold of >2.3 for gain.
Assay methods
Details of Affymetrix Oncoscan Version 1 results with clinical and histopathologic patient characteristics have been reported (17) . Briefly, MIP probes are hybridized to genomic DNA and split into two tubes containing paired nucleotide mixes (triphosphates of adenine þ thymine or cytosine þ guanine). In the presence of DNA polymerase and ligase, MIP probes circularize with their complementary nucleotide. Allele discrimination is enzymatically derived and highly specific, allowing multiplexed assays. Of 1,003 case samples, 971 passed quality control and included.
We followed two approaches to compute copy number at LRIG1. Preprocessing included application of the Nexus Copy Number Segmentation algorithm to each of the samples. We extracted copy number information from 11 of 12 probes that passed quality control (call rate >90%, relative SD <0.4) located within the start and stop locations of LRIG1 assembly UCSC hg18 (NCBI Build 36.1); 16.9% of calls were removed as outliers. To quantify copy number, we identified the segment that contained the start-end locations of LRIG1 (chromosome 3: 66,511,911-66,633,535), with each sample having distinct start and stop sites. The copy number assigned to the LRIG1 "locus" is the mean value of that region as reported by Nexus Copy Number. Thus, the per-tumor locus that includes LRIG1 is large [median (mean) length of 12.05 (14.16 ) mb] relative to the LRIG1 locus (122 kb). The segmentation yielded a median (mean) number of probes/segment of 1,183 (1, 313) . The distributions of segment lengths and probes are illustrated in Supplementary Fig. S1A and S1B.
In the second case, we focused the location of our previous LRIG1 probe, which was positioned at 66,527,771 to 66,531,685 (intron 10 spanning exon 11). The MIP probes located at 66,515,866 and 66,532,949 were closest to the exons. To reduce noise generated from using single exon-flanking probes, we calculated copy number from all evaluable probes 5 0 and 3 0 of exon 12. For these "intra-gene" analyses, the median of the first five probes 5 0 of exon 12 are designated LRIG1 [1] [2] [3] [4] [5] , and the median of the last 6 probes located 3 0 of exon 13 are designated LRIG1 [6] [7] [8] [9] [10] [11] ( Supplementary Fig. S2 ). To account for the inherent noise, normal contamination, and possible effects of mosaisicm on copy number determination, we applied a threshold for copy number gain in LRIG1 as >2.3 and loss as <1.7, as reported previously. To determine the impact of the threshold selection on any observed associations, we conducted a series of sensitivity analyses across a range of copy number thresholds for the determination of LRIG1 gain or loss. The application of stringent thresholds under an assumption of pure tumor cells produced the magnitude and direction of the association though our power was reduced. The results of the sensitivity analyses indicate that the associations were not sensitive to the selection of thresholds.
Statistical analyses
We used Fisher exact test to examine the association between LRIG1 copy number variation and ERBB2 status or intrinsic subtype. The Spearman rank correlation coefficient was used to assess the correlation between the logarithm of copy number at the ERBB2 locus and the LRIG1 locus. We conducted the Kruskal-Wallis test for differences in LRIG1 copy number across the different intrinsic subtypes and Cox proportional hazards regression for survival analysis. For patient outcomes of any relapse (local and distant, n ¼ 252), a clinical-only multivariate Cox model was built. In the first step, all covariates shown in Table 1 were included; then stepwise selection was performed to minimize Akaike Information Criterion (AIC), which resulted in a reduced clinical model with diagnosis age, tumor size, and nodal status. These 3 selected covariates were included in multivariate Cox models with various outcomes (recurrence, distant metastasis, and overall survival).
Results
LRIG1, patient, and tumor characteristics
Of 971 stage I/II breast tumors, 3.9% had LRIG1 gene-level gains, whereas 8.9% showed losses ( Table 1 ). The overall distribution of LRIG1 copy number status (loss, normal, or gain) differed significantly by tumor subtype (P ¼ 0.005) and by race/ethnicity (P ¼ 0.03). LRIG1 loss was more common in TNBC (13.8%) and HER2 þ (12.3%) tumors than luminal B (9.7%) and luminal A (4.8%) tumors. Median LRIG1 copy number differed significantly among the four subtypes (P < 0.0001; Supplementary Fig. S3 ). Furthermore, copy number loss was more prevalent in black (12.8%) and Hispanic (12.2%) cases than NHWs (7.7%); distribution reflects a higher proportion of TNBC and HER2 þ tumors in these patients ( Supplementary  Table S1 ). There were no overall differences in LRIG1 copy number status by tumor stage, diagnosis age, nuclear grade, tumor size, lymph node status, or treatment (yes/no or type; Table 1 ). Furthermore, unlike previous smaller studies of more-advanced tumors, copy number gains in the LRIG1 LRIG1 copy number 5 0 and 3 0 to exon 12 and clinicopathologic characteristics We previously hypothesized a putative breakpoint in LRIG1 with gain of exon 11 coincident with ERRB2 amplification (13) . Using MIP data in the LRIG1 locus, we conducted two statistical tests comparing log-copy number values of two regions for all possible 11-probe partitions. Both tests produced a minimum P value for comparing the regions 5 0 versus 3 0 to exon 12 independent of any a priori fitting (P ¼ 2.04 À46 and 3.36 À49 for a Wilcoxon rank-sum test and a t test, respectively). These results support our prior hypothesis of a common breakpoint in LRIG1 occurring near the exon 12/13 junction.
Overall, partitioned data of the smaller intragene events in tumors reflect those using the whole probe set ( Supplementary  Table S2 ). For the loci 5 0 of exon 12 (LRIG1 1-5 ), 20.9% of cases had gains and 14.9% showed loss. Losses in the 5 0 region were significantly more common in black (20.8%) and Hispanic (20.3%) cases than in NHW patients (13%). Gains in the region did not differ significantly by patient or tumor characteristics with the exception that gains of LRIG1 1-5 were $3-fold higher in ER þ /HER2 þ tumors than ER À /HER2 þ tumors (27.8% vs. 11.9%, respectively, P ¼ 0.008). Events at the 3 0 partitioned loci (LRIG1 6-11 ) were slightly less frequent than those occurring 5 0 to exon 12 with 10.0% and 19.8% of tumors showing gains or losses, respectively. Copy number in the region 3 0 of exon 12 showed significant differences by race/ethnicity, ER status, and treatment. Specifically, loss of this region was more common among black (28%) and Hispanic (22%) cases than NHW (18.2%; P ¼ 0.04). Gains in this region were more common in ER þ (11.3%) than ER À (7.5%) tumors (P ¼ 0.08), with losses more common in ER À than ER þ tumors (23.9% vs. 18.0%, respectively, P ¼ 0.04).
LRIG1 copy number and relapse risk
In univariate analyses, LRIG1 loss was significantly associated with time-to-relapse, with a nonsignificant trend for lower overall survival (Fig. 1A) , for both early (<5 years) and late (!5 years) events (Fig. 1B) . The 5-year cut-point was selected based on the clinical relevance of this time point for patients and the arbitrary consideration of "late" recurrences being those that occur after 5 years. For example, when we excluded recurrences that occurred <5 years after diagnosis, the probability of relapse was 46% in patients with LRIG1 loss compared with only 28% in patients with normal copy number. However, when we applied the scaled Schoenfeld residuals, plotted against time, there was no statistically significant time trend of the effect of LRIG1 gain or loss (P values for linear trend ¼ 0.23 for losses). If anything, we find that LRIG1 loss shows the biggest effect between 2 and 7 years from diagnosis and remains independent of the other clinicopathologic characteristics. When adjusted for diagnosis age, tumor size, and nodal status associated relapse risk, LRIG1 loss was significantly associated with recurrence (HR, 1.91; 95% CI, 1.33-2.74), distant metastasis (HR, 2.10; 95% CI, 1.43-3.09) and overall mortality (HR, 1.55; 95% CI, 1.11-2.16; Table 2 ). The increased hazard remained even after forcing in treatment and tumor subtype (data not shown). Although the effect of LRIG1 loss was generally similar in treated and untreated cases, risk of relapse was stronger and more immediate in untreated patients (Supplementary Table S3 ). However, we observed no association between LRIG1 gain and relapse or overall mortality (data not shown).
Chromosome 3 copy number analyses support LRIG1 as a major driver event at 3p12-21
Gains and losses at chromosome 3p12-21 are common and heterogeneous across breast tumors. To investigate the contribution of LRIG1 to the associations found for chromosome 3 overall, we first generated a high-resolution noise-reduced profile for each sample, applying the quantification method used for LRIG1 in a priori hypothesis testing to the rest of chromosome 3, and assigning a copy number value to each chromosome 3 probe (n ¼ 17,557) for each sample. Because we were interested in LRIG1 copy number losses, we conservatively designated loss for each probe of the smoothed data as copy number <À1.7 and fit a Cox model adjusted for age, tumor size, and nodal status. We calculated log 10 P values for the association of loss with relapse across chromosome 3 and a small (178 kb) region that includes LRIG1 and SLC25A26 (cytogenic band at 3p14), which is positively associated with disease recurrence ( Fig. 2A and B ). In addition, we computed the average overlap with LRIG1 for each probe ( Supplementary  Fig. S4 ). The only probes showing low P values for association with recurrence were those with high LRIG1 overlap. We also used percent agreement of the loss/no-loss calls for each probe with the LRIG1 loss/no-loss calls and found that the few probes with very high (>99%) correlation with LRIG1 loss showed small P values for recurrence, and all probes belonged to either LRIG1 or SLC25A26.
Association between LRIG1 loss and recurrence is independent of loss at fragile histidine triad
Deletions on 3p are thought to arise as a consequence of frequent breaks because of the presence of a common fragile site encompassed by fragile histidine triad (FHIT), a set of highly unstable genomic regions at 3p14.2 (13, 14) FHIT is abnormally transcribed in 30% of breast tumors (18) and has been associated with poor outcomes (19) . In our dataset, FHIT loss was highly correlated with LRIG1 loss (R 2 ¼ 0.55; P < 0.0001). To eliminate FHIT as an explanation for our observed associations between LRIG1 copy number and patient outcomes, we conducted a multivariate model adjusted for FHIT loss; LRIG1 loss remained significantly associated with relapse risk (HR, 2.01; 95% CI, 1.15-3.52; P ¼ 0.01).
LRIG1 gene expression and patient outcomes
For further evidence that LRIG1 copy number may explain the previous association between losses of 3p12-121 and worse patient outcomes (5), we evaluated 18 publicly available gene expression datasets with breast cancer outcomes, yielding 1,576 samples with information on distant metastasis-free Methods) . The risk of DMFS and death were significantly higher in patients with breast cancer whose tumors expressed low LRIG1 levels compared with medium or high expression ( Fig. 3) . Importantly, as with the copy number analyses, the risk persists beyond 5 years after diagnosis. Furthermore, to rule out a contribution from SLC25A26, we tested the association between SLC25A26 gene expression and patient outcomes using publicly available data. Although the sample set is smaller because of differences in probe availability of platforms for SLC25A26, unlike its neighbor LRIG1, we observed no evidence for an association between SLC25A26 expression level and DMFS or overall mortality ( Supplementary Fig. S5 ). In contrast, low LRIG1 expression levels were positively associated with higher rates of distant metastasis and mortality, even in the smaller sample set.
Discussion
Our findings support those of Staaf and colleagues (15) , which show that genomic loss near 3p13 in breast tumors is an independent risk factor for relapse and poor survival. Our results strongly implicate LRIG1 loss as the major driver event in this region, with localized deletion or low LRIG1 gene expression significantly associated with distant metastasis and breast cancer death. Importantly, the increased hazard persists in these patients beyond 5 years postdiagnosis, suggesting the loss may be a strong indicator of late events in otherwise lowrisk patients.
The higher frequency of loss in black and Hispanic women was positively associated with higher LRIG1 loss in TNBC, HER2 þ , and luminal B tumors; subtypes that are disproportionally higher in these patients ( Supplementary Table S2 ). In contrast to our previous report (13) , we observed no Cancer Research 2932 significant association between LRIG1-specific copy number imbalances and ERBB2 amplification, although specific probe losses were significantly more common among ER À tumors, and gains were more common in ER þ disease. Among HER2 þ tumors, gains in LRIG1 were more common among ER þ /HER2 þ than HER2 þ /ER À tumors, consistent with an overall higher frequency of gains in ER þ versus ER À tumors and losses in ER À versus ER þ tumors. Given the complex pattern of splicing in LRIG1, additional analyses of expressed transcripts may provide further insight and risk stratification among patient populations.
Our data confirm previous reports of amplification in the LRIG1 gene region (9); however, we were unable to replicate our prior observation (13) of concomitant gains in LRIG1 and ERBB2 amplification. Similar to Krig and colleagues (14), we observed a significant association between gains and ER þ tumors and nonsignificantly better patient outcomes (data not shown). Our findings support those of Miller and colleagues (4), which suggest LRIG1 loss is more common in tumor subtypes with disturbances in ErbB family members (i.e., ERBB2 amplification in ER À /HER2 þ tumors and EGFR in TNBCs). Analyses of probes flanking exon 12/13 favor our original hypothesis for a breakpoint in the gene, possibly reflecting localized fragility involving FHIT that destabilizes the region (76/86 tumors bearing LRIG1 loss also show FHIT loss). LRIG1 protein has been shown to oppose MET synergy with HER2 in cellular invasion and to negatively regulate other oncogenic receptor tyrosine kinases in the ErbB family, including EGFR, HER3 and 4, MET, and RET (4). These functional data support a key role of LRIG1 as a tumor suppressor gene important in limiting tumor invasion, a putative mechanism that aligns with our finding of greater metastasis risk in cases with LRIG1 loss.
In our previous study, we showed increased copy number at exon 12/13 in LRIG1 in 34% of 73 breast tumors (12, 13) . Moreover, we observed coincident ERBB2 gene amplification in tumors with gain of exon 12/13 probe signal. In contrast, LRIG1 expression was reported to be downregulated in HER2overexpressing tumors (4) . There are several possible explanations for differences between our earlier results and this study. First, the Oncoscan array did not provide any probes at the exact genomic location of our previous FISH probe and confidence with few MIP probes is limited, thus the results are not directly comparable. Second, the prior results analyzed a smaller and more selected set of cases including patients with larger and more-advanced tumors.
In conclusion, our results provide strong evidence that LRIG1 is the tumor suppressor gene on chromosome 3 near p13-14 whose loss is a critical driver event in breast cancer metastasis that is independent of stage and tumor subtype. Although LRIG1 loss is proportionally higher in TNBC and HER2 þ tumors, loss in otherwise low-risk cases (e.g., luminal A) may partly explain late relapse events in these patients. Along with efforts to understand the mechanistic impact of LRIG1 loss on degradation of ErbB family members and control of tumor stem cells in the breast, prospective efforts that combine gene expression and copy number determination of LRIG1 are needed to confirm the clinical value of LRIG1 expression status for patient-risk stratification.
